Nano-based approved pharmaceuticals for cancer treatment : present and future challenges

Francisco Rodríguez, Pablo Caruana, Noa De la Fuente, Pía Español, Maria Gámez, Josep Balart, E.. Llurba, Ramon Rovira Negre, Raúl Ruiz, Cristina Martín-Lorente, José Luis Corchero Nieto, María Virtudes Céspedes

Research output: Contribution to journalReview articleResearchpeer-review

121 Citations (Scopus)

Abstract

Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe unde-sirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments.
Original languageEnglish
JournalBiomolecules
Volume12
Issue number6
DOIs
Publication statusPublished - 2022

Keywords

  • Nanomedicine
  • Cancer therapy
  • Nanotechnology
  • Approved nanopharmaceuticals
  • Targeted therapy

Fingerprint

Dive into the research topics of 'Nano-based approved pharmaceuticals for cancer treatment : present and future challenges'. Together they form a unique fingerprint.

Cite this